These findings highlight the potential importance of treatment persistence in maximizing the cardioprotective benefits of GLP-1RAs
If a person develops these complications from GLP-1 drug use, they will require emergency care and hospitalization
Nooms philosophy is that sustainable results come from coupling pharmacotherapy with behavior change , in accordance with FDA guidance
Ten patients received semaglutide 1.0 mg, and one patient each received semaglutide 0.5 mg, liraglutide 1.2 mg and liraglutide 2.4 mg (maximum tolerated dose)
Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation)usually mild to moderate and often diminishing over time Injection site reactions Headache Fatigue More serious but rare adverse effects have been identified, including: Pancreatitis patients should seek urgent medical advice for severe, persistent abdominal pain (with or without vomiting) Gallbladder disease symptoms include upper right abdominal pain and jaundice Diabetic retinopathy complications particularly with rapid HbA1c reduction in patients with pre-existing retinopathy Dehydration and acute kidney injury from persistent gastrointestinal symptoms When combined with sulfonylureas or insulin, GLP-1 receptor agonists increase the risk of hypoglycaemia
